Akela Enhances Its Manufacturing Capabilities With Spray Drying Technology

PharmaForm, a wholly owned subsidiary of Akela Pharma has enhanced its portfolio of bioavailability enhancement solutions by adding aqueous and solvent spray drying.

PharmaForm claimed that its processing technology, spray drying offers a number of benefits to optimise drug formulation, including enhanced bioavailability of poorly soluble compounds, higher drug loading and predictable scale-up.

The company said that in addition to the new spray drying capability, the Akela’s comprehensive bioavailability enhancement technologies include hot-melt extrusion, solvent-based fluid bed processing and liquid filled hard capsules.

Gregory McKee, president and CEO of Akela, said: “PharmaForm’s investment in the Anhydro MicraSpray 35 is part of the company’s strategic focus and commitment to provide comprehensive solutions for poorly soluble compounds. Spray drying further enables us to better serve our clients by offering another proven, commercializable technology to enhance bioavailability and accelerate their drug development programs.”